TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis

Lignende værker

• Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis
  af: Kim, Dong Geon, et al.
  Udgivet: (2015)
• Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2
  af: Lee, Weon Sup, et al.
  Udgivet: (2018)
• ACTR-75. A MULTICENTER, 3-ARM, OPEN-LABEL, PHASE IIA CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF TANIBIRUMAB (VEGFR2 MAB), IN PATIENTS WITH RECURRENT GBM ASSESSED WITH K-TRANS AND INITIAL AREA UNDER THE GADOLINIUM CONCENTRATION-TIME CURVE (IAUGC)
  af: Cher, Lawrence, et al.
  Udgivet: (2017)
• Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model
  af: Kim, Jinil, et al.
  Udgivet: (2018)
• KDR (VEGFR2) Genetic Variants and Serum Levels in Patients with Rheumatoid Arthritis
  af: Agnieszka Paradowska-Gorycka, et al.
  Udgivet: (2019-08-01)